Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Summary

The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.

Timeline

Start

2017-12-21

Primary completion

2021-01-01

Completion

2021-01-01

Drugs

Indications